VA-REGULA
7.3.2024 08:01:27 CET | Business Wire | Press release
Liveness detection, both for individuals and their IDs, has become a cornerstone for a secure customer onboarding process. It is especially crucial in remote scenarios where document submission and verification are done via the Internet. With 65% of organizations globally relying on digital document checks in their online identity verification workflows, robust anti-fraud measures cannot be overrated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306499292/en/
Regula Document Reader SDK verifies the authenticity of an ID by checking its optically variable features (Photo: Business Wire)
Responding to this growing need for additional fraud protection, Regula has released an update for its Regula Document Reader SDK, a comprehensive solution for the most reliable and secure identity document verification. Thanks to improved neural networks, detecting and analyzing an identity document has become twice as fast. The software is now able to check dynamic security features that were previously eligible for verification in on-site scenarios only. These checks include, but are not limited to:
- Optically Variable Ink (OVI), which changes color depending on the angle of observation and illumination;
- Lenticular images, such as Multiple Laser Image (MLI) and Dynaprint, which consist of several initial images that appear depending on the angle of observation;
- Holograms, which reflect and form an image in reflected light when changing the angle of observation and illumination.
The updated Regula Document Reader SDK can reliably validate the authenticity of an ID by verifying such optically variable features. The solution employs advanced algorithms to analyze the presence of these features and images in documents, as well as their exact location, their content, and their liveness—e.g., changing colors, images, etc.—based on a specific document template. All a user needs to do is show their ID in front of a smartphone camera, and the rest is technology. With advanced document liveness detection, Regula Document Reader SDK effectively prevents identity fraud and other types of fraud, such as printed photo attacks and screen replay attacks.
Apart from that, all the client-side data retrieved during liveness checks and verification sessions can be securely transferred in encrypted form to the backend client’s server. Captured document images, session video, RFID session data, document liveness session data, and other processing data can be used to re-process a verification session in a customer’s trusted environment. This “zero-trust-to-mobile” approach adds an important layer of trustworthiness to the verification process, as it ensures that no data is manipulated by fraudsters while being transferred from mobile devices.
“Today, a mere $15 is all it takes to get an AI-generated ID — a golden ticket to illicit banking and crypto operations, and to circumventing anti-money laundering protocols. Amid this digital wild west, the necessity for document liveness checks has never been more critical. They serve as an essential counter-fraud measure, preventing identity theft and document tampering. By ensuring that a real document is being presented during onboarding, you can significantly enhance the verification process to prove that it is genuine and not a counterfeit or digital replica. That’s why we never stop researching and improving the functionality of Regula Document Reader SDK,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the recent update of Regula Document Reader SDK, please visit the official webpage.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306499292/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
